S86 Factors associated with non-fatal atrial fibrillation or flutter within the first 30 days post-exacerbation of COPD: a nested case-control study
Emily L. Graul(Emory University), Jennifer K Quint(Roland Hill (United Kingdom)), Kirsty Rhodes(AstraZeneca (United Kingdom)), Andreas A. Ioannides(Imperial College London), Clémentine Nordon(AstraZeneca (United Kingdom)), Constantinos Kallis(Imperial College London), Hannah Whittaker(Imperial College London), Jonathan Marshall(AstraZeneca (United Kingdom)), NS Peters(Imperial College London), Shruti Menon(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
|EBioMedicine|2022|121
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
|Nature Medicine|2023|96
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America
|The Journal of Allergy and Clinical Immunology In Practice|2022|79
Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
|American Journal of Respiratory and Critical Care Medicine|2023|79